Imugene Limited (ASX: IMU) is into the operations of immuno-oncology. It is in its clinical stage and is into the development of a range of new and novel immunotherapies which helps to activate the immune system of cancer patients to treat and eradicate tumours. The company has a unique platform technology that tries to harness the immune system of the body to generate antibodies against tumours, in order to get a similar or greater response than synthetically manufactured monoclonal antibody therapies.
The company today on 14 March 2019 announced that it had given a dose of its HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients to the first patient in an open-label, randomised multi-centre Phase 2 study. The patient in the study was dosed at the Oncological Institute in Chisinau, the capital of Moldova, in Eastern Europe. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
HER-Vaxx is a potentially pioneering vaccine for cancer treatments. The vaccine produces antibody which is a response against a cancer growth signal receptor protein (HER-2). This is found on the cell surface of multiple cancers including breast and gastric cancers.
The MD and CEO of the company Leslie Chong said, that after the good results seen in the recently completed Phase 1b trial there is a strong medical investigator interest. In the trial, 11 out of 14 evaluable patients showed clinically meaningful responses. The company will provide regular recruitment updates as the Phase 2 study moves toward completion in 2020. It is an important achievement for the company to have commenced the Phase 2 study, and important for several medical professionals as well, who are looking out for treatments for patients who does not have many medical options after being diagnosed with advanced HER-2 positive gastric cancer.
As per the report of the Phase 1b HER-Vaxx study, there are no safety or toxicity issues. All patients evaluated responded with an increased antibody. One patient saw a complete response, five had a partial response, and four recorded a stabilisation of their disease.
The Phase 2 HER-Vaxx study has been an indicator of success, safety and the immune response in sixty-eight patients who are diagnosed with metastatic gastric cancer. Across multiple sites in Asia, Eastern Europe and India this Phase 2 trial is being conducted, where it is difficult for patients to access approved antibody treatments such as Herceptinâ and Perjetaâ, which is marketed by Swiss multinational Roche Holding AG.
On the price-performance front, the stock of Imugene Limited is currently trading at $0.020 with an increase of ~5.26 per cent during the day’s trade, with a market capitalisation of $68.59 million (AEST 01:29 PM). The stock has generated a YTD return of 5.56% and a negative return of 17.39% over the past six months. It had a 52-week high price of $0.040 and a 52-week low price of $0.015, with an average trading volume of ~4.28 million.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.